The FDA’s recent guidance on submitting next-generation sequencing data to the Division of Antiviral Products provides additional clarity around how sequencing data should be generated, analysed, documented, and interpreted when used to support resistance monitoring, antiviral efficacy, and molecular characterisation. For many sponsors, this introduces additional regulatory considerations. For us, the guidance serves as formal recognition of many of the principles and practices that have long underpinned our approach to NGS data generation, analysis, interpretation, and reporting.
The practical implication is clear: sponsors will need sequencing workflows that are not only technically robust, but also biologically interpretable, fully traceable, and capable of withstanding regulatory scrutiny.
Sequencing can identify nucleotide changes, but it cannot determine their biological significance. It cannot distinguish between natural viral evolution, analytical artefacts, and genuine resistance-associated variants. Those answers require an understanding of viral biology, the clinical context of the sample, and the relationship between genotype and phenotype. That is why our NGS capability was built within a specialised virology laboratory rather than operating as a standalone sequencing service. By integrating sequencing with virology expertise, we ensure that sequence data are interpreted within the biological context needed to generate meaningful and actionable insights. The FDA’s emphasis on biological relevance and interpretability closely aligns with this approach.
The guidance also highlights the importance of validated workflows, reproducibility, and transparent documentation. These are foundational requirements for any organisation generating NGS data to support antiviral development programmes. Our sequencing pipelines were designed for programmes where sample integrity, chain of custody, and analytical consistency are critical. This centralised model reduces operational variability, enables rapid issue resolution, and ensures that data are generated within a fully traceable and validated framework.
One of the most significant challenges in antiviral sequencing is distinguishing between natural variation in the influenza genome and variants associated with antiviral treatment. Viruses such as influenza evolve continuously, meaning that the use of an outdated or inappropriate reference sequence can generate long lists of apparent variants that are not biologically meaningful. Without careful consideration of viral epidemiology, evolution, and reference selection, sequence comparisons can become misleading. The result may be an inflated number of reported variants that simply reflect differences between the study virus and the chosen reference genome. The downstream implications of this are substantial. Every reported variant may require justification during regulatory review, and, in some cases, sponsors must demonstrate whether specific variants influence antiviral susceptibility. When variant lists contain large numbers of artefactual findings, that burden increases significantly.
For antiviral development programmes, the principles highlighted in the guidance are clear: sequencing data must be generated using well documented and robust methods, interpreted within the appropriate biological context, supported by careful reference selection, and capable of informing meaningful resistance assessments. These are not isolated technical requirements but interconnected components of a regulatory-ready sequencing strategy.
Our NGS capability has been shaped by the demands of antiviral development. It was built to support high-volume respiratory pathogen studies, integrate seamlessly with clinical operations, and provide molecular insights that inform real-time decision-making throughout development programmes. Years of analysing clinically derived viral isolates and monitoring resistance patterns across diverse studies have refined both our analytical workflows and scientific interpretation framework. As part of a broader infectious disease laboratory ecosystem, sequencing is not performed in isolation but alongside the virology expertise required to translate sequence data into biological understanding.
More broadly, the FDA’s guidance reflects the increasing importance of biologically meaningful sequencing data in antiviral development. As NGS becomes more deeply embedded within regulatory submissions, the focus will shift beyond generating sequence data to demonstrating that those data are accurate, interpretable, reproducible, and clinically relevant. Organisations that combine robust sequencing capabilities with deep virology expertise will be best positioned to meet these evolving expectations. We welcome the additional clarity the guidance provides and are proud to support sponsors with sequencing, resistance monitoring, and molecular intelligence that already align with these expectations today and will continue to evolve alongside future regulatory requirements.